RxDoctor Payments Data

Miguel Cossio, MD

Internal Medicine · Madison, GANPI 1669426557

Payments from drug & device makers

$1,765in general payments, 2019–2025

Across 66 payments — averaging $26.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$837
  • Novo Nordisk$360
  • Lilly USA, LLC$189
  • Sanofi-aventis U.S. LLC$99
  • GSK$85
  • Otsuka America Pharmaceutical, Inc.$72
  • plus $123 from 5 others

What the payments were for

  • Food & beverage$1,759100%
  • Education$60%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,765 in reported general payments places this provider in the 70th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$165,376
Medicare patients
183
Services billed
3,273

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol121$121,259
EliquisApixaban177$105,507
OzempicSemaglutide78$73,260
JardianceEmpagliflozin71$59,302
MounjaroTirzepatide43$53,854
XareltoRivaroxaban66$48,295
JanuviaSitagliptin Phosphate59$44,332
LinzessLinaclotide26$31,182
EntrestoSacubitril/Valsartan21$30,614
Tresiba Flextouch U-100Insulin Degludec21$27,632
TradjentaLinagliptin19$10,826
Humulin 70/30 KwikpenInsulin Nph Hum/Reg Insulin Hm11$10,418
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$8,804
Janumet XrSitagliptin Phos/Metformin Hcl13$7,990
Rosuvastatin Calcium481$5,753

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$837$135,002147 claims
Novo NordiskOzempic, Novolog$360$75,90998 claims
Lilly USA, LLCMounjaro$189$53,85443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,311 internal medicine providers in Georgia.

Other internal medicine in Madison

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →